Denis Monneret

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5502121/publications.pdf

Version: 2024-02-01

304743 1,997 78 22 h-index citations papers

44 g-index 86 86 86 2953 citing authors docs citations times ranked all docs

243625

#	Article	IF	CITATIONS
1	High-sensitive cardiac troponin after CPAP in obstructive sleep apnoea: the adjusted analytical change limit (adjACL) for small variations at low concentrations. European Respiratory Journal, 2022, 59, 2103022.	6.7	O
2	Relationships between renal function variations and relative changes in cardiac troponin T concentrations based on quantile generalized additive models (qgam). Clinical Chemistry and Laboratory Medicine, 2021, 59, 1115-1125.	2.3	1
3	Stability of lactate in venous blood gas and sodium fluoride-potassium oxalate plasma: a 6-year retrospective database analysis. Clinical Chemistry and Laboratory Medicine, 2021, 59, e438-e441.	2.3	1
4	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. European Journal of Gastroenterology and Hepatology, 2020, 32, 998-1007.	1.6	8
5	Passage of uranium through human cerebral microvascular endothelial cells: influence of time exposure in mono- and co-culture inÂvitro models. International Journal of Radiation Biology, 2020, 96, 1597-1607.	1.8	3
6	Homeostasis model assessment of insulin resistance and lobular inflammation in nondiabetic patients with nonalcoholic fatty liver disease: methodological considerations. European Journal of Gastroenterology and Hepatology, 2020, 32, 542-542.	1.6	O
7	Non-linearity and gaps in results distribution over successive Roche Lipase method applications: improvement but persistence. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 572-578.	1.2	1
8	External validation of an algorithm combining multiâ€analyte blood tests (FibroTest‣CR1‣CR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease. GastroHep, 2019, 1, 146-153.	0.6	3
9	Reference percentiles for paired arterial and venous umbilical cord blood gases: An indirect nonparametric approach. Clinical Biochemistry, 2019, 67, 40-47.	1.9	7
10	Outlier removal methods for skewed data: impact on age-specific high-sensitive cardiac troponin T 99th percentiles. Clinical Chemistry and Laboratory Medicine, 2019, 57, e244-e247.	2.3	1
11	S100B Serum Elevation Predicts In-Hospital Mortality After Brain Arteriovenous Malformation Rupture. Stroke, 2019, 50, 1250-1253.	2.0	7
12	Treating hepatic encephalopathy in cirrhotic patients admitted to <scp>ICU</scp> with sodium phenylbutyrate: a preliminary study. Fundamental and Clinical Pharmacology, 2018, 32, 209-215.	1.9	17
13	Determination of age- and sex-specific 99th percentiles for high-sensitive troponin T from patients: an analytical imprecision- and partitioning-based approach. Clinical Chemistry and Laboratory Medicine, 2018, 56, 818-829.	2.3	27
14	Sample management for clinical biochemistry assays: Are serum and plasma interchangeable specimens?. Critical Reviews in Clinical Laboratory Sciences, 2018, 55, 480-500.	6.1	42
15	Wide-range CRP versus high-sensitivity CRP on Roche analyzers: focus on low-grade inflammation ranges and high-sensitivity cardiac troponin T levels. Scandinavian Journal of Clinical and Laboratory Investigation, 2018, 78, 346-351.	1.2	9
16	Estimated GFR-specific 99th percentiles for high-sensitive cardiac troponin T based on the adjusted analytical change limit (adjACL) in hospitalized patients. Clinical Chemistry and Laboratory Medicine, 2018, 57, e5-e7.	2.3	4
17	N-terminalÂpro-brainÂnatriuretic peptide: a potential follow-up biomarker of mandibular advancement device efficacy on cardiac function in obstructive sleep apnea. F1000Research, 2018, 7, 1818.	1.6	1
18	N-terminalÂpro-brainÂnatriuretic peptide: a potential follow-up biomarker of mandibular advancement device efficacy on cardiac function in obstructive sleep apnea. F1000Research, 2018, 7, 1818.	1.6	1

#	Article	IF	CITATIONS
19	Comment on direct bilirubin as predictor of severity and mortality in idiopathic pulmonary arterial hypertension. International Journal of Cardiology, 2017, 239, 35.	1.7	2
20	Serum lipid profile, sleep-disordered breathing and blood pressure in the elderly: a 10-year follow-up of the PROOF-SYNAPSE cohort. Sleep Medicine, 2017, 39, 14-22.	1.6	10
21	Serum sCD163 as a biomarker of adipose tissue inflammation in obstructive sleep apnoea patients: limits and perspectives. European Respiratory Journal, 2017, 50, 1701038.	6.7	0
22	Impact of pH on Urine Chemistry Assayed on Roche Analyzers. Clinical Laboratory, 2017, 63, 1749-1753.	0.5	1
23	Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations. F1000Research, 2017, 6, 1669.	1.6	1
24	Stability of Routine Biochemical Analytes in Whole Blood and Plasma From Lithium Heparin Gel Tubes During 6â€hr Storage. Journal of Clinical Laboratory Analysis, 2016, 30, 602-609.	2.1	27
25	Plasma endothelinâ \in 1 in acute heart failure: pathophysiological and preanalytical considerations. European Journal of Heart Failure, 2016, 18, 579-579.	7.1	2
26	Introducing High-Sensitivity Cardiac Troponin T as a Biomarker of OSA-Related Cardiovascular Morbidity in Obesity Hypoventilation Syndrome. Chest, 2016, 150, 1408-1409.	0.8	1
27	Potassium as a potential predictive biomarker of brain hypoxia in avalanche victims: preanalytical recommendations. American Journal of Emergency Medicine, 2016, 34, 1315-1316.	1.6	1
28	Intermittent hypoxia in obese Zucker rats: cardiometabolic and inflammatory effects. Experimental Physiology, 2016, 101, 1432-1442.	2.0	18
29	Endothelin regulates intermittent hypoxiaâ€induced lipolytic remodelling of adipose tissue and phosphorylation of hormoneâ€sensitive lipase. Journal of Physiology, 2016, 594, 1727-1740.	2.9	28
30	Analytical Performance Requirements for Biomarker-based Studies Evaluating Continuous Positive Airway Pressure Effects in Obstructive Sleep Apnea. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 522-523.	5.6	0
31	Glucose tolerance and cardiovascular risk biomarkers in non-diabetic non-obese obstructive sleep apnea patients: Effects of long-term continuous positive airway pressure. Respiratory Medicine, 2016, 112, 119-125.	2.9	21
32	Paradoxical decrease in isoprostane and increase in superoxide dismutase following CPAP withdrawal in OSA. European Respiratory Journal, 2016, 47, 1012-1014.	6.7	4
33	Comparison of a 10- vs. 15-min centrifugation time for chemical and immunochemical assays and impact on turnaround time in a hospital laboratory. Clinical Chemistry and Laboratory Medicine, 2016, 54, e117-21.	2.3	7
34	Sleep quality, sleep duration and physical activity in obese adolescents: effects of exercise training. Pediatric Obesity, 2016, 11, 26-32.	2.8	79
35	High-Sensitivity Cardiac Troponin T: a Preanalytical Evaluation. Clinical Laboratory, 2016, 62, 743-8.	0.5	5
36	Letter by Monneret et al Regarding Article, "Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study― Circulation: Heart Failure, 2015, 8, 1009-1009.	3.9	2

#	Article	lF	Citations
37	Blood-brain barrier dysfunction assessed by protein S-100 beta levels in cirrhotic patients in ICU. Intensive Care Medicine Experimental, 2015, 3, .	1.9	1
38	Hemolysis indexes for biochemical tests and immunoassays on Roche analyzers: Determination of allowable interference limits according to different calculation methods. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 162-169.	1.2	40
39	P0141 : Blood-brain barrier dysfunction assessed by Protein S-100 beta levels in cirrhotic patients. Journal of Hepatology, 2015, 62, S354.	3.7	O
40	Comparison of measured venous carbon dioxide and calculated arterial bicarbonates according to the PaCO2 and PaO2 cut-off values of obesity hypoventilation syndrome. Clinical Chemistry and Laboratory Medicine, 2015, 53, e343-6.	2.3	1
41	Evaluation of HbA1c as a prognostic biomarker of cardiovascular events and mortality in nondiabetic patients: Methodological considerations. Atherosclerosis, 2015, 242, 19-21.	0.8	3
42	Bicarbonate or Base Excess in Early Obesity Hypoventilation Syndrome. Chest, 2015, 147, e231.	0.8	5
43	S100B protein concentration measurement according to two different immunoassays. Clinical Chemistry and Laboratory Medicine, 2015, 53, e169-71.	2.3	6
44	Impact of exercise training without caloric restriction on inflammation, insulin resistance and visceral fat mass in obese adolescents. Pediatric Obesity, 2015, 10, 311-319.	2.8	43
45	Endothelin regulates intermittent hypoxia-induced lipolytic remodelling of adipose tissue and phosphorylation of hormone-sensitive lipase. , 2015, , .		0
46	Analytical comparison of the new point-of-care troponin T immunoassay on AQT90Flex® analyzer (Radiometer) and the high-sensitivity troponin T immunoassay on ModularE170® (Roche Diagnostics). Clinical Chemistry and Laboratory Medicine, 2014, 52, e279-82.	2.3	4
47	Cytokines in pulmonary arterial hypertension: consider sensitivity when using multiplex technology. European Respiratory Journal, 2014, 44, 547-549.	6.7	4
48	P1039 APPLICABILITY (APP) CRITERIA FOR REAL-TIME SHEAR WAVE ELASTOGRAPHY (RT-SWE) BY AIXPLORER COMPARED TO TRANSIENT ELASTOGRAPHY (TE) BY FIBROSCAN AND TO FIBROTEST. Journal of Hepatology, 2014, 60, S421.	3.7	0
49	P1024 PRESENCE OF HEPATIC STEATOSIS AS PER NON-INVASIVE BIOMARKERS OVERESTIMATES FIBROSIS STAGES BASED ON LIVER STIFFNESS MEASUREMENT (LSM) BY TRANSIENT ELASTOGRAPHY IN TYPE-2 DIABETIC (T2D) PATIENTS. Journal of Hepatology, 2014, 60, S416.	3.7	0
50	Isoprostane as a promising prognostic biomarker in pulmonary arterial hypertension: preanalytical and analytical viewpoints. International Journal of Cardiology, 2014, 177, 527-528.	1.7	2
51	Respective effects of OSA treatment and angiotensin receptor blocker on aldosterone in hypertensive OSA patients: A randomized cross-over controlled trial. International Journal of Cardiology, 2014, 177, 629-631.	1.7	15
52	Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. Alimentary Pharmacology and Therapeutics, 2014, 40, 1081-1093.	3.7	27
53	Isoprostane as oxidative stress biomarker in the VARIAFIT study: Analytical and methodological considerations. Diabetes and Metabolism, 2014, 40, 316-317.	2.9	2
54	Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini�― Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 432-439.	1.5	10

#	Article	IF	CITATIONS
55	Myocardial Injury after Noncardiac Surgery. Anesthesiology, 2014, 120, 564-578.	2.5	740
56	Evaluation of LOCI® technology-based thyroid blood tests on the Dimension Vista® analyzer. Clinical Biochemistry, 2013, 46, 1290-1297.	1.9	13
57	The Severity of Nocturnal Hypoxia but Not Abdominal Adiposity Is Associated with Insulin Resistance in Non-Obese Men with Sleep Apnea. PLoS ONE, 2013, 8, e71000.	2.5	32
58	Altitude illness is related to low hypoxic chemoresponse and low oxygenation during sleep. European Respiratory Journal, 2012, 40, 673-680.	6.7	55
59	Independent Association of Urinary F2-Isoprostanes With Survival in Pulmonary Arterial Hypertension. Chest, 2012, 142, 869-876.	0.8	50
60	Corticosteroid after etomidate in critically ill patients. Critical Care Medicine, 2012, 40, 29-35.	0.9	77
61	Noninvasive Ventilation in Mild Obesity Hypoventilation Syndrome. Chest, 2012, 141, 692-702.	0.8	133
62	The impact of obstructive sleep apnea on homocysteine and carotid remodeling in metabolic syndrome. Respiratory Physiology and Neurobiology, 2012, 180, 298-304.	1.6	22
63	Reduced six-minute walking distance, high fat-free-mass index and hypercapnia are associated with endothelial dysfunction in COPD. Respiratory Physiology and Neurobiology, 2012, 183, 128-134.	1.6	32
64	Obesity hypoventilation syndrome: From sleepâ€disordered breathing to systemic comorbidities and the need to offer combined treatment strategies. Respirology, 2012, 17, 601-610.	2.3	62
65	Sleep deprivation, sleep apnea and cardiovascular diseases. Frontiers in Bioscience - Elite, 2012, E4, 2007.	1.8	47
66	High-Altitude Illness And Hypoxic Chemoresponsivness: A Unifying View Of Individual Susceptibility. , 2011, , .		0
67	Cardiovascular And Metabolic Consequences Of Chronic Intermittent Hypoxia In Lean Versus Obese Zucker Rats., 2011,,.		O
68	The Impact Of Obstructive Sleep Apnea On Homocysteine And Carotid Remodelling In Patients With Metabolic Syndrome. , $2011, \ldots$		0
69	Effects Of CPAP And Valsartan Randomly Assigned On Baroreflex Function And Aldosterone In Hypertensive OSAS., 2011,,.		1
70	Significant Improvement in Arterial Stiffness After Endurance Training in Patients With COPD. Chest, 2010, 137, 585-592.	0.8	67
71	Association of urinary 15-F2t-isoprostane level with oxygen desaturation and carotid intima–media thickness in nonobese sleep apnea patients. Free Radical Biology and Medicine, 2010, 48, 619-625.	2.9	45
72	Association Of Urinary 15-F2t-isoprostane Level With Oxygen Desaturation And Carotid Intima-media Thickness In Non-obese Sleep Apnea Patients. , 2010, , .		0

#	ARTICLE	IF	CITATION
73	One-month Of Non-Invasive Ventilation In Obesity Hypoventilation Syndrome Improves Sleep Architecture And Blood Gazes But Has No Impact On Inflammatory, Metabolic And Cardiovascular Status: A Randomized Controlled Trial. , 2010, , .		O
74	Pleiotropic role of IGF-I in obesity hypoventilation syndrome. Growth Hormone and IGF Research, 2010, 20, 127-133.	1.1	25
75	Endothelial Dysfunction and Specific Systemic Inflammation in Obesity Hypoventilation Syndrome, 2009, , .		1
76	Endothelial Dysfunction and Specific Inflammation in Obesity Hypoventilation Syndrome. PLoS ONE, 2009, 4, e6733.	2.5	70
77	ENDOTHELIAL DYSFUNCTION AND SPECIFIC SYSTEMIC INFLAMMATION IN OBESITY HYPOVENTILATION SYNDROME. Chest, 2009, 136, 104S.	0.8	O
78	Plasma 15-F2t isoprostane concentrations are increased during acute fructose loading in type 2 diabetes. Diabetes and Metabolism, 2008, 34, 148-154.	2.9	19